Drug Ther Bull. 2011 Apr;49(4):45-8; quiz iii-iv. doi: 10.1136/dtb.2011.02.0025.
Estimates suggest that over 3 million people in the UK have chronic obstructive pulmonary disease (COPD).1 Drug management for the condition includes treatments to relieve respiratory symptoms, and prevent and treat acute exacerbations.2,3 ▾Roflumilast (Daxas - Merck Sharp & Dohme) is the first marketed drug in a new class (selective oral phosphodiesterase 4 [PDE4] inhibitors), "aimed at targeting COPD inflammation"4 and licensed as maintenance treatment for severe COPD.5 Here we discuss its place in the management of patients with COPD.
据估计，英国有超过300万人患有慢性阻塞性肺疾病（COPD）。1 该疾病的药物治疗包括缓解呼吸道症状以及预防和治疗急性加重的疗法。2,3 罗氟司特（达赛克斯 - 默克雪兰诺）是新型药物类别（选择性口服磷酸二酯酶4 [PDE4] 抑制剂）中首个上市的药物，“旨在针对COPD炎症”4 并被许可用于重度COPD的维持治疗。5 在此，我们讨论其在COPD患者管理中的地位。
